Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits. The biotech ...

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...